Hikma Pharmaceuticals Public annual book value per share
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Book Value Per Share Growth & History (HIK)
Hikma Pharmaceuticals Public's book value per share was $11.78 for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.78 | $1.30 | +12.42% |
| 2024 | 2024-12-31 | $10.48 | $0.54 | +5.41% |
| 2023 | 2023-12-31 | $9.94 | $0.25 | +2.56% |
| 2022 | 2022-12-31 | $9.69 | -$0.93 | −8.73% |
| 2021 | 2021-12-31 | $10.62 | $1.58 | +17.43% |
| 2020 | 2020-12-31 | $9.05 | — | — |
Hikma Pharmaceuticals Public quarterly book value per share
Q4.24
Q2.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.99 | $0.53 | +4.61% |
| Q4 2025 | 2025-12-31 | $11.78 | $1.30 | +12.42% |
| Q2 2025 | 2025-06-30 | $11.46 | — | — |
| Q4 2024 | 2024-12-31 | $10.48 | — | — |
Hikma Pharmaceuticals Public book value per share trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's book value per share increased from $9.05 to $11.78, a change of $2.74. The latest reported quarter, Q2 2026, shows $11.99.
About the metric
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
Calculation and source
How book value per share is calculated
TickerStat calculates book value per share as reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...